Intriguingly, BTNL2 is primarily expressed in the small intestinal epithelium and appears to function as a negative regulator of T-cell activation (12), with mutations in this protein conferring increased risk of inflammatory bowel disease (IBD) (13). Here, BTNL2 is linked to inflammatory bowel disease.